IR (cm-1): 1811 (br s, Al–H). Anal. Calcd for C39H54AlLiN2O4: C,
72.20; H, 8.39. Found: C, 72.56; H, 8.17.
1
13
(t, 3JHH = 7.6 Hz, 4H). { H} C NMR (75 MHz, CD2Cl2): d 25.2
(CH2), 26.1 (CH2), 26.5 (CH2), 34.2 (CH2), 58.9 (N–CH), 68.3
(THF), 113.8 (CH), 114.6 (CH), 119.2 (CH), 125.9 (CH), 146.5
(Cipso), 147.9 (Cipso). 7Li NMR (155.5 MHz, CD2Cl2): d -0.14 (s).
IR (cm-1): 1751 (br s, Al–H). Anal. Calcd for C28H40AlLiN2O2: C,
71.47; H, 8.57. Found: C, 71.15; H, 8.32.
g2-N, N -{((C5H9)N-o-C6H4)2O}Al(l-OCH2Ph)2Li(THF)2 (5a).
In a glovebox, two equivalents of benzaldehyde (245 mL,
2.42 mmol) were added via a syringe to a precooled (-35 ◦C)
THF solution (10 mL) of the Al hydrido species 2a. The initial
colorless solution turned immediately yellow upon addition of
PhCHO; it was then allowed to warm to room temperature and
stirred overnight at this temperature. The resulting yellow solution
was then evaporated to dryness to afford a yellow residue as the
crude product, which was recrystallized at -35 ◦C from a 1/5
THF/pentane solvent mixture to afford compound 5a as a pale
{(CyN-o-C6H4)2O}Al(H)(THF) (3b) NMR-scale reaction.
A
J-Young NMR tube containing a CD2Cl2 solution of pure 2b was
1
left for 24 h at RT. Subsequent H NMR analysis revealed the
complete conversion of the Al salt species 2b into the neutral
monohydrido aluminium complex 3b, along with formation of
CHD2Cl (d 2.99, q, 2JHD = 1.6 Hz). Preparative scale. In a glove
box, a CH2Cl2 of complex 2b (200 mg, 0.425 mmol) was stirred
at room temperature overnight to yield, after drying in vacuo,
a pale light suspension (formation of LiCl), which was filtered
through a glass frit to afford a colorless foam as the crude product.
Recrystallization of the latter residue from a 9/1 pentane/CH2Cl2
solvent mixture stored at -5 ◦C afforded pure 3b (277 mg, 63%
1
yellow powder in pure form (400.0 mg, 50% yield). H NMR
(300 MHz, CD2Cl2): d 1.49–1.53 (m, 4H, C5H9), 1.68–1.88 (m,
20H, C5H9 and Hb-THF), 3.50 (m, 8H, Ha-THF), 3.87 (m, 2H,
3
N–CH), 4.76 (s, 4H, PhCH2), 6.47 (t, JHH = 7.5 Hz, 2H), 6.88
3
(d,, JHH = 8.1 Hz, 2H), 6.97–7.03 (m, 4H), 7.20–7.30 (m, 10H).
1
13
{ H} C NMR (75 MHz, CD2Cl2): d 24.5 (CH2), 25.3 (THF),
31.0 (CH2), 59.7 (N–CH), 65.4 (PhCH2), 67.9 (THF), 112.9 (CH),
116.4 (CH), 118.0 (CH), 124.9 (CH), 126.2 (CH), 126.7 (CH),
127.9 (CH), 144.9 (Cipso), 147.5 (Cipso), 147.8 (Cipso). Anal. Calcd
for C44H56AlLiN2O5: C, 72.71; H, 7.77. Found: C, 73.05; H, 7.92.
1
yield). H NMR (300 MHz, CD2Cl2): d 1.14–1.33 (m, 8H, Cy),
1.59–1.82 (m, 16H, Cy and Hb-THF), 2.78 (br s, 1H, Al–H), 3.09
(br s, 2H, N–CH), 3.73 (br s, 4H, Ha-THF), 6.44 (t, 3JHH = 7.6 Hz,
3
3
2H), 6.70 (d, JHH = 8.1 Hz, 2H), 6.79 (d, JHH = 7.8 Hz, 2H),
6.96 (t, 3JHH = 7.7 Hz, 2H). { H} C NMR (75 MHz, CD2Cl2): d
24.8 (CH2), 25.9 (CH2), 26.3 (CH2), 36.3 (CH2), 55.9 (N–CH), 69.9
(THF), 110.7 (CH), 111.1 (CH), 116.2 (CH), 125.8 (CH), 144.1
(Cipso), 145.6 (Cipso). IR (cm-1): 1842 (br s, Al–). Anal. Calcd for
C28H39AlN2O2: C, 72.70; H, 8.50. Found: C, 72.93; H, 8.77.
1
13
g2-N,N-{(CyN-o-C6H4)2O}Al(l-OCH2Ph)2Li(THF)2
(5b).
The dialkoxide Al complex 4b was synthesized following an
identical procedure to that used for 5a and was isolated as
an analytically pale yellow powder from a 1/5 THF/pentane
solvent mixture cooled at -35 ◦C (630 mg, 42% yield). 1H NMR
(300 MHz, CD2Cl2): d 1.08–1.29 (m, 8H, Cy), 1.55–1.62 (m, 8H,
Hb-THF), 1.71–1.78 (m, 8H, Cy), 1.91–2.04 (m, 4H, Cy), 3.09 (m,
2H, N–CH), 3.25 (m, 8H, Ha-THF), 4.83 (s, 4H, PhCH2), 6.44
g2-N,
N -{(C5H9)N-o-C6H4)2O}Al(H)(l-OCH2Ph)Li(THF)2
(4a). The mono-alkoxide species 4a was synthesized using an
identical procedure to that for 5a (vide infra) but using one
equivalent of benzaldehyde. Compound 5a was isolated as a
colorless solid after recrystallization of the crude product at
3
(t, JHH = 7.5 Hz, 2H), 6.87–6.96 (m, 6H), 7.17–7.28 (m, 10H).
1
13C{ H} NMR (75 MHz, CD2Cl2): d 25.0 (CH2), 25.3 (CH2),
◦
-35 C from a 1/5 THF/pentane solvent mixture (352 mg, 47%
yield). H NMR (300 MHz, CD2Cl2): d 1.41–.55 (m, 4H, C5H9),
25.9 (CH2), 33.3 (CH2), 58.8 (N–CH), 65.4 (PhCH2), 67.9 (THF),
112.9 (CH), 115.6 (CH), 118.4 (CH), 124.2 (CH), 126.3 (CH),
126.8 (CH), 126.0 (CH), 144.9 (Cipso), 146.9 (Cipso), 148.5 (Cipso).
Anal. Calcd for C46H60AlLiN2O5: C, 73.19; H, 8.01. Found: C,
73.56; H, 8.21.
1
1.61–1.82 (m, 20H, C5H9 and Hb-THF), 3.50 (m, 8H, Ha-THF),
3.91 (m, 2H, N–CH), 4.65 (s, 2H, PhCH2), 6.37 (t, 3JHH = 7.5 Hz,
3
2H), 6.81 (d, JHH = 8.1 Hz, 2H), 7.01–7.09 (m, 4H), 7.27–7.35
1
13
(m, 5H). { H} C NMR (75 MHz, CD2Cl2): d 24.4 (CH2), 25.6
(CH2), 31.8 (CH2), 60.0 (N–CH), 65.9 (PhCH2), 68.5 (THF),
113.9 (CH), 116.7 (CH), 117.5 (CH), 125.1 (CH), 126.3 (CH),
126.9 (CH), 128.4 (CH), 144.4 (Cipso), 147.52 (Cipso), 148.1 (Cipso).
IR (cm-1): 1805 (br s, Al–H). Anal. Calcd for C37H50AlLiN2O4: C,
71.79; H, 8.12. Found: C, 72.21; H, 7.98.
{(CyN-o-C6H4)2O}Al(OCH2Ph)(THF) (6b). NMR-scale reac-
tion. In a J-Young NMR tube, the Al hydrido complex 3b
(30.0 mg, 0.053 mmol) was charged and dissolved in CD2Cl2
(0.75 mL) and one equivalent of benzaldehyde (5.4 mL,
0.053 mmol) was immediately added via a microsyringe to the
latter solution. The NMR tube was tightly capped, vigorously
shaken and a 1H NMR spectrum was immediately recorded show-
ing the quantitative formation of the Al alkoxide 6b. Preparative
scale. In a glove box, one equivalent of benzaldehyde (35.7 mL,
0.352 mmol) was added via a microsyringe to a precooled CH2Cl2
g2-N, N -{(CyN-o-C6H4)2O}Al(H)(l-OCH2Ph)Li(THF)2 (4b).
The mono-alkoxide species 4b was synthesized using an identical
procedure to that for 5b (vide infra) but using one equivalent
of benzaldehyde. Compound 5b was isolated as a colorless solid
after recrystallization of the crude product at -35 ◦C from a 1/5
◦
solution (-35 C, 10 mL) of complex 3b (200 mg, 0.352 mmol).
1
THF/pentane solvent mixture (274 mg, 45% yield). H NMR
The resulting mixture was left under stirring at room temperature
overnight and subsequently evaporated to dryness to afford a
colorless solid as the crude pro◦duct. Recrystallization of the latter
residue in Et2O stored at -35 C afforded pure 6b as a colorless
(300 MHz, CD2Cl2): d 1.10–1.33 (m, 8H, Cy), 1.66–1.73 (m, 8H,
Hb-THF), 1.71–1.82 (m, 8H, Cy), 1.95–2.09 (m, 4H, Cy), 3.06 (m,
2H, N–CH), 3.49 (m, 8H, Ha-THF), 4.70 (s, 2H, PhCH2), 6.38 (t,
1
13
1
3JHH = 7.5 Hz, 2H), 6.91–7.06 (m, 6H), 7.14–7.34 (m, 5H). { H} C
NMR (75 MHz, CD2Cl2): d 25.2 (CH2), 26.3 (CH2), 27.2 (CH2),
33.7 (CH2), 34.3 (CH2), 58.7 (N–CH), 64.2 (PhCH2), 67.9 (THF),
111.5 (CH), 113.3 (CH), 119.0 (CH), 125.1. (CH), 125.8 (CH),
126.8 (CH), 127.0 (CH), 145.1 (Cipso), 147.4 (Cipso), 148.8 (Cipso).
powder (112 mg, 56% yield). H NMR (300 MHz, CD2Cl2): d
1.16–1.34 (m, 4H, Cy), 1.64–1.89 (m, 20H, Cy and Hb-THF), 2.99
(br m, 2H, N–CH), 3.41 (m, 4H, Ha-THF), 4.52 (s, 2H, PhCH2),
3
3
6.45 (t, JHH = 7.6 Hz, 2H), 6.76 (d, JHH = 7.6 Hz, 2H), 6.92
3
(d, JHH = 7.6 Hz, 2H), 6.93–7.03 (m, 4H), 7.12–7.28 (m, 3H).
This journal is
The Royal Society of Chemistry 2010
Dalton Trans., 2010, 39, 533–540 | 539
©